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Abstract
Aims In the initial 26-week, double-blind, double-dummy assessment period of the DURATION-2 trial in patients with
Type 2 diabetes on metformin, the once-weekly glucagon-like peptide 1 (GLP-1) receptor agonist exenatide once-weekly
resulted in greater HbA1c improvement and weight reduction compared with maximum approved daily doses of sitagliptin or
pioglitazone. This subsequent, 26-week, open-label, uncontrolled assessment period evaluated the safety and efﬁcacy of (i)
continued exenatide once-weekly treatment and (ii) switching from sitagliptin or pioglitazone to exenatide once-weekly.
Methods Randomised oral medications were discontinued and all patients received exenatide once-weekly. Of the 364
patients [original baseline HbA1c 8.5  1.1% (70 mmol⁄mol), fastingplasmaglucose 9.0  2.5 mmol⁄l, weight 88  20 kg)
who continued into the open-label period, 319 patients (88%) completed 52 weeks.
Results Evaluable patients who received only exenatide once-weekly demonstrated signiﬁcant 52-week improvements (least
square mean  se)i nH b A 1c ()1.6  0.1%), fasting plasma glucose ()1.8  0.3 mmol⁄l) and weight ()1.8  0.5 kg).
Evaluablepatientswhoswitchedfromsitagliptintoexenatideonce-weeklydemonstratedsigniﬁcantincrementalimprovements
in HbA1c ()0.3  0.1%), fasting plasma glucose ()0.7  0.2 mmol⁄l) and weight ()1.1  0.3 kg). Patients who switched
from pioglitazone to exenatide once-weekly maintained HbA1c and fasting plasma glucose improvements (week 52:
)1.6  0.1%, )1.7  0.3 mmol⁄l), with signiﬁcant weight reduction ()3.0  0.3 kg). Exenatide once-weekly was generally
welltoleratedandadverseeventswerepredominantlymildormoderateinintensity.Nauseawasthemostfrequentadverseevent
in this assessment period (intent-to-treat: exenatide once-weekly-only 5%; sitagliptin ﬁ exenatide once-weekly 11%;
pioglitazone ﬁ exenatide once-weekly 10%). No major hypoglycaemia was observed.
Conclusions Patientswhoswitchedtoonce-weeklyexenatidefromdailysitagliptinorpioglitazonehadimprovedorsustained
glycaemic control, with weight loss.
Diabet. Med. 28, 705–714 (2011)
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Introduction
In an attempt to address treatment concerns of many traditional
medications for Type 2 diabetes, the most recent American
Diabetes Association⁄European Association for the Study of
Diabetes(ADA⁄EASD)[1]andAmericanAssociationofClinical
Endocrinologists⁄American College of Endocrinology (AACE⁄
ACE)[2]algorithmsinclude,asadjunctivetherapytometformin,
newer classes of medications that may positively inﬂuence some
of the metabolic abnormalities associated with Type 2 diabetes
(obesity, dyslipidaemia and other cardiovascular risk factors). In
the DURATION-2 double-blind, double-dummy trial, three
reasonable choices of add-on therapy were directly compared
in patients with Type 2 diabetes not adequately controlled
with metformin monotherapy. After 26 weeks of treatment,
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receptor agonist exenatide resulted in superior improvements in
glycaemic control and body weight compared with maximum
approved doses of the dipeptidyl peptidase-4 (DPP-4) inhibitor,
sitagliptin, and the thiazolidinedione, pioglitazone [3].
In the subsequent, open-label phase of the DURATION-2
trial, all patients received exenatide once-weekly. Rather than
adding another medication, as is common in clinical practice,
patients who originally received daily sitagliptin or pioglitazone
discontinuedtheirrespectiveoraltreatmenttoassessincremental
changes in glycaemic control and body weight after switching to
once-weekly administration of exenatide. Patients originally
randomised to exenatide once-weekly continued treatment and
discontinuedoralplacebo.Inthisopen-labelextensionperiod,all
patients continued metformin background therapy, andpatients
and investigators remained blinded to original treatment. This
trial was designed to evaluate the glycaemic and non-glycaemic
(body weight, blood pressure, fasting lipids, markers of
cardiovascular risk) changes in patients: (i) treated with
exenatide once-weekly for 52 weeks; (ii) who switched from
daily inhibition of DPP-4 (which elicits an approximately
twofold increase in circulating postprandial GLP-1 [4]) to a
therapy that results in continuous exposure to greater
concentrations of the GLP-1 receptor agonist exenatide; and
(iii) who switched from daily peroxisome proliferator-activated
receptor gamma (PPAR-c) stimulation with pioglitazone, which
increases insulin sensitivity, but is also often associated with
increased body weight, to a therapy that augments glucose-
dependent insulin secretion and is associated with weight loss.
Patients and methods
Design overview
DURATION-2, a randomised, double-blind, double-dummy,
multi-center clinical trial conducted in the USA, India and
Mexico was designed as a two-stage trial. In the ﬁrst phase, the
efﬁcacyandsafetyof26 weeksoftreatmentwithexenatideonce-
weekly were compared with maximum approved doses of
sitagliptin or pioglitazone in patients with Type 2 diabetes
mellitus treated with metformin [3]. In this second, open-label
phase, randomised oral medications were discontinued and all
patients received exenatide once-weekly.
Randomization and interventions
Eligible patients were male and non-pregnant female patients, at
least18 yearsofage,withType 2diabetesmellitus,butotherwise
healthy and treated with a stable regimen of metformin for a
minimum of 2 months prior to screening. Additional inclusion
criteriaincludedHbA1c7.1–11.0%(54–97 mmol⁄mol)andBMI
25–45 kg⁄m
2[3].Patients(n = 514)wereoriginallyrandomised
to one of three treatment groups by UBC Clinical Technologies
(San Francisco, CA, USA) via an interactive voice response
system: exenatide once-weekly (2 mg) subcutaneous injection
(self-administered) plus placebo once daily in the morning
capsule, sitagliptin (100 mg) once daily in the morning plus
placebo once-weekly injection, or pioglitazone (45 mg) once
daily in the morning plus placebo once-weekly injection. All
patients,thestudy-sitestaff,theinvestigatorandthesponsorwere
blinded to the identity of study medication during the double-
blind treatment period. Randomization was stratiﬁed according
to country and screening HbA1c stratum [< 9% (< 75 mmol⁄
mol), ‡ 9% (‡ 75 mmol⁄mol)]. In the second, open-label phase
of DURATION-2, randomised oral medications were
discontinued and all patients received 2 mg exenatide once-
weekly treatment; patients and investigators were not notiﬁed of
originaltreatment.Acommonclinicalprotocolwasapprovedfor
each site by the appropriate Ethical Review Board. Patients
provided written informed consent prior to participation. This
study was conducted in accordance with the Declaration of
Helsinki(1946),includingthecurrentSeoulrevision(2008),and
consistent with Good Clinical Practice and applicable laws and
regulations.
Outcomes
Study endpoints included change from baseline to weeks 26 and
52, and change from week 26 to week 52, in HbA1c,p a t i e n t s
achieving HbA1c targets of < 7.0% (< 53 mmol⁄mol) and
£ 6.5% (£ 48 mmol⁄mol), change in fasting plasma glucose
(target £ 7 mmol⁄l), body weight, fasting lipids, fasting insulin,
systolicanddiastolicbloodpressure,cardiovascularriskmarkers
(urinary albumin⁄creatinine ratio, B-type natriuretic peptide,
high-sensitivity C-reactive protein and plasminogen activator
inhibitor-1), safety and tolerability. Plasma and urine analytes
and HbA1c were quantitated by Quintiles Laboratories
(Marietta, GA, USA; Mumbai, India; and Singapore) using
standard methods. All other measures were performed as
previously described [3].
Treatment-emergent adverse events were deﬁned as those
occurring for the ﬁrst time or worsening after the ﬁrst dose of
exenatide once-weekly during the open-label period. Hypoglyc-
aemiawascategorizedasmajororminor.Majorhypoglycaemia
was deﬁned as being associated with (i) a loss of consciousness,
seizureorcoma,whichresolvedafteradministrationofglucagon
or glucose or (ii) severe impairment in consciousness or
behaviour that required third-party assistance to resolve and a
glucose value of < 3 mmol⁄l. Minor hypoglycaemia was deﬁned
as a report of symptoms consistent with hypoglycaemia and a
glucose value of < 3 mmol⁄l prior to treatment of the episode.
Statistical analysis
The open-label intent-to-treat population used for all safety
analyses consisted of all subjects who completed the 26-week
double-blinded treatment period and they received one dose of
open-label once-weekly exenatide at a timepoint after week 26.
The 52-week evaluable population consisted of the open-label
intent-to-treat patients who completed the study visits to at least
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studymedicationexposureinthisassessmentperiod(‡ 145 days
of exenatide once-weekly; £ 2 doses missed during the last
2 months). There were no substantial differences in HbA1c
between the exenatideonce-weekly-only 52-week evaluable and
intent-to-treatpopulations(Fig. 1);therefore,demographicsand
theanalysisofnon-safetyendpointsareprovidedforthe52-week
evaluable population.
AnalysesofchangeinHbA1cfrombaselinetoweeks 26and52
were based on a general linear model, including factors for
treatment, country and baseline HbA1c stratum. Change in
HbA1c during the open-label phase (weeks 26–52) was analysed
based on a general linear model, including factors for treatment,
countryandHbA1cvaluesatweek 26asacovariate.Analysesof
changeinothervariablesfrombaselinetoweeks 26and52were
based on a general linear model, including factors for treatment,
country, baseline HbA1c stratum and corresponding baseline
value as a covariate. Change in other variables during the open-
label phase were analysed based on a general linear model,
including factors for treatment, country and corresponding
valuesofvariablesatweek 26asacovariate.Log-transformation
was applied to triglycerides and cardiovascular risk markers
before ﬁtting the model. Comparison of proportions achieving
HbA1c and fasting plasma glucose targets between week 26 and
week 52 within each treatment group was performed using a
McNemar test. Mean change from baseline for efﬁcacy
endpoints was expressed as least square means. Statistical tests
were conducted two-sided at a signiﬁcance level of 0.05 using
SAS (version 9.2; SAS Institute, Cary, NC, USA).
Results
Patient disposition and baseline characteristics
Demographics and baseline characteristics for the 52-week
evaluable population were similar between treatment arms
(Fig. 2) and 87–89% of patients completed this 26-week
open-label period, regardless of initial therapy. The most
common reason for withdrawal was withdrawal of consent in
patients originally receiving exenatide once-weekly (7%) and
sitagliptin (4%), while withdrawal because of an adverse event
was most common (7%) among patients originally randomised
to pioglitazone.
Glycaemic control
Patients who received exenatide once-weekly for 52 weeks
sustained the initial 26-week improvements in HbA1c [least
square mean change from original baseline (95% CI)] at
week 52: )1.6% ()1.9 to )1.3%); Fig. 3. Patients who
switched from pioglitazone to exenatide once-weekly
treatment also maintained HbA1c improvement [week 52:
)1.6% (95% CI )1.8 to )1.3%)], while patients who
switched from sitagliptin to exenatide once-weekly exhibited a
signiﬁcant incremental reduction in HbA1c ()0.3%;
P = 0.0010), resulting in a 52-week HbA1c reduction of )1.4%
(95% CI )1.7 to )1.2%). No signiﬁcant changes in the
proportion of patients who achieved the HbA1c targets of
<7 % ( <5 3m m o l⁄mol) and £ 6.5% (£ 48 mmol⁄mol) at
week 52 compared with week 26 were observed for
patients who originally received exenatide once-weekly or
pioglitazone; signiﬁcantly more patients achieved both HbA1c
targets after switching from sitagliptin to exenatide once-weekly
(Fig. 3).
Exenatide once-weekly-only and pioglitazone ﬁ exenatide
once-weekly patients also maintained fasting plasma glucose
improvements from week 26 to week 52 (Fig. 3), while patients
originally randomised to sitagliptin exhibited signiﬁcant further
fasting plasma glucose improvements ()0.7 mmol⁄l;
P = 0.0017). At the end of this assessment period, the
proportion of patients who achieved fasting plasma glucose
£ 7 mmol⁄l was unchanged with exenatide once-weekly-only
(week 26 ﬁ week 52: 62% ﬁ 62%) and following the switch
from pioglitazone to exenatide once-weekly (week 26 ﬁ
week 52: 59% ﬁ 59%). Signiﬁcantly more patients achieved
fasting plasma glucose £ 7m m o l⁄l after switching from
sitagliptin to exenatide once-weekly (week 26 ﬁ week 52:
38% ﬁ 58%; P = 0.0002).
Body weight
Patients who switched from pioglitazone to exenatide once-
weekly exhibited a signiﬁcant weight reduction ()3.0 kg;
P < 0.0001; Fig. 3), such that body weight was similar to
original baseline weight by week 52. Patients originally treated
with sitagliptin also exhibited a signiﬁcant reduction in weight
afterswitching to exenatide once-weekly ()1.1 kg; P = 0.0006).
Patients who received exenatide once-weekly throughout the
trial on average had a + 0.7 kg (P = 0.0325) increase in weight
from week 26 to week 52, resulting in a )1.8  0.5 kg
(P = 0.0002) reduction from original baseline.
FIGURE 1 Least square mean  se HbA1c change over 52 weeks in
52-week evaluable and open-label intent-to-treat (ITT) patients who were
originally randomised to receive exenatide once weekly at the start of the
study.
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SystolicbloodpressurechangesarepresentedinTable 1.Patients
with abnormal baseline systolic blood pressure (‡ 130 mmHg)
treated with exenatide once-weekly for 52 weeks (n = 42)
exhibited greater systolic blood pressure improvements
[)12.2 mmHg (95% CI )16.1 to )8.3)]. Patients who
exhibited abnormal systolic blood pressure at week 26 after
Randomised 
514
Demographics and baseline characteristics
(52-week evaluable,  n = 103)
Sex (%)
  Male 59 (57%)
Female 44 (43%)
Race/ethnicity (%)
Caucasian 33 (32%)
Black 11 (11%)
Hispanic 34 (33%)
Asian 25 (24%)
  Native American 0
  Other 0
Age (years) 52 ± 10
Weight (kg) 90 ± 19
Body mass index (kg/m
2)3 2 ± 5
HbA1c (%) 8.6 ± 1.2
Fasting glucose (mmol/l) 9.3 ± 2.9
Duration of diabetes (years) 6±5
Withdrew 33 (20.6%)
Withdrawal of consent 13 (8.1%)
Adverse event 11 (6.9%)
Investigator decision 0
Protocol violation 1 (0.6%)
Lost to follow-up 5 (3.1%)
Administrative 2 (1.3%)
Loss of glucose control 1 (0.6%)
Withdrew prior to first dose of medication
23
Withdrawal of consent 10 (1.9%)
Adverse event 1 (0.2%)
Investigator decision 1 (0.2%)
Protocol violation 4 (0.8%)
Lost to follow-up 7 (1.4%)
2 mg exenatide once-weekly
Intent-to-treat 160
Withdrew 22 (13.3%)
Withdrawal of consent 4 (2.4%)
Adverse event 5 (3.0%)
Investigator decision 3 (1.8%)
Protocol violation 2 (1.2%)
Lost to follow-up 7 (4.2%)
Administrative 0
Loss of glucose control 1 (0.6%)
100 mg sitagliptin 
Intent-to-treat 166
Withdrew 34 (20.6%)
Withdrawal of consent 15 (9.1%)
Adverse event 6 (3.6%)
Investigator decision 1 (0.6%)
Protocol violation 0
Lost to follow-up 11 (6.7%)
Administrative 0
Loss of glucose control 1 (0.6%)
45 mg pioglitazone 
Intent-to-treat 165
2 mg exenatide once-weekly
Open-label intent-to-treat 119 
2 mg exenatide once-weekly
Open-label intent-to-treat 130 
2 mg exenatide once-weekly
Open-label intent-to-treat 115
Withdrew 16 (13.4%)
Withdrawal of consent 8 (6.7%)
Adverse event 1 (0.8%)
Investigator decision 1 (0.8%)
Protocol violation 1 (0.8%)
Lost to follow-up 2 (1.7%)
Administrative 1 (0.8%)
Loss of glucose control 2 (1.7%)
Withdrew 14 (10.8%)
Withdrawal of consent 5 (3.8%)
Adverse event 3 (2.3%)
Investigator decision 1 (0.8%)
Protocol violation 0
Lost to follow-up 2 (1.5%)
Administrative 2 (1.5%)
Loss of glucose control 1 (0.8%)
Demographics and baseline characteristics
(52-week evaluable, n = 116)
Sex (%)
  Male 67 (58%)
Female 49 (42%)
Race/ethnicity (%)
Caucasian 41 (35%)
Black 12 (10%)
Hispanic 30 (26%)
Asian 31 (27%)
Native American 2 (2%)
  Other 0
Age (years) 53 ± 11
Weight (kg) 88 ± 21
Body mass index (kg/m
2)3 2 ± 5
HbA1c (%) 8.5 ± 1.1
Fasting glucose (mmol/l) 9.0 ± 2.5
Duration of diabetes (years) 6±5
Withdrew 15 (13.0%)
Withdrawal of consent 5 (4.3%)
A d v e r s ee v e n t 8( 7 . 0 % )
Investigator decision 0
Protocol violation 0
Lost to follow-up 1 (0.9%)
Administrative 0
Loss of glucose control 1 (0.9%)
Demographics and baseline characteristics
(52-week evaluable, n = 100)
Sex (%)
  Male 51 (51%)
Female 49 (49%)
Race/ethnicity (%)
Caucasian 39 (39%)
Black 4 (4%)
Hispanic 27 (27%)
Asian 29 (29%)
  Native American 0
  Other 1 (1%)
Age (years) 53 ± 10
Weight (kg) 86 ± 21
Body mass index (kg/m
2)3 2 ± 5
HbA1c (%) 8.4 ± 1.0
Fasting glucose (mmol/l) 8.9 ± 2.1
Duration of diabetes (years) 6 ± 5
Open-label exenatide once-weekly-only phase
FIGURE 2 Patient disposition and demographics [mean  sd or n (%)].
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demonstrated a greater systolic blood pressure reduction
[)11.3 mmHg (95% CI )14.9 to )7.7) and )9.4 mmHg
(95% CI )13.4 to )5.3), respectively; week 26 to week 52].
Changes in concomitant anti-hypertensive medications were
only allowed if deemed necessary by the investigator. Of the 186
(a) (b)
(c)
(e)
(d)
FIGURE 3 Change in glycaemic control and body weight. (a) Least square (LS) mean  se change in HbA1c in 52-week evaluable patients over 52 weeks.
Change from week 26 to week 52 is presented in ﬁgure insert. (b) Per cent of 52-week evaluable patients achieving HbA1c t a r g e t<7 %( <5 3m m o l⁄mol) at
week 26 and week 52. (c) LS mean  se change in fasting plasma glucose in 52-week evaluable patientsover 52 weeks. Change from week 26 to week 52 is
presented in ﬁgure insert. (d) Per cent of 52-week evaluable patients achieving HbA1c target £ 6.5% (£ 48 mmol⁄mol) at week 26 and week 52. (e) LS
mean  se change in body weight in 52-week evaluable patients over 52 weeks. Change from week 26 to week 52 is presented in ﬁgure insert. *P < 0.05.
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open-label assessment period, 172 patients (99, 87 and 93% of
patients originally randomised to exenatide once-weekly,
sitagliptin and pioglitazone, respectively) did not change dose
and two patients (n = 1 sitagliptin ﬁ exenatide once-weekly;
n = 1 pioglitazone ﬁ exenatide once-weekly) initiated
medication after the start of the open-label period.
Patients who continued exenatide once-weekly for 52 weeks
maintained improvement in HDL cholesterol from baseline; all
otherlipidvariableswerenotsigniﬁcantlychangedfromoriginal
baseline (Table 1). Patients who switched from sitagliptin to
exenatide once-weekly also maintained the HDL cholesterol
improvement observed during the initial 26 weeks of treatment
andexperiencedasigniﬁcantreductionintotalcholesterolinthis
open-label treatment period. Patients who switched from
pioglitazone to exenatide once-weekly signiﬁcantly reduced
HDL cholesterol, LDL cholesterol and total cholesterol and
increased triglycerides. Of the 132 patients who used a lipid-
lowering agent at the start of the 26-week open-label assessment
period, 121 patients (91, 89 and 95% of patients originally
randomised to exenatide once-weekly, sitagliptin and
pioglitazone, respectively) did not change dose and 13 patients
(n = 3 exenatide once-weekly-only; n = 5 sitagliptin ﬁ
exenatide once-weekly; n = 5 pioglitazone ﬁ exenatide once-
weekly) started a lipid-lowering medication after the start of the
open-label period.
Exenatide once-weekly for 52 weeks was associated with
improvements in the urinary albumin⁄creatinine ratio, B-type
natriuretic peptide and high-sensitivity C-reactive protein
(Table 2). Although the mean urinary albumin⁄creatinine ratio
reductions in both groups that switched to exenatide once-
weekly were not statistically signiﬁcant during this treatment
period, the urinary albumin⁄creatinine ratio was signiﬁcantly
reduced from original baseline in all three treatment arms.
Of note, urinary creatinine was not signiﬁcantly different from
baselinetoweek 52inanytreatmentarm.Patientswhoswitched
from sitagliptin or pioglitazone to once-weekly exenatide
signiﬁcantly reduced B-type natriuretic peptide, while the high-
sensitivity C-reactive protein and plasminogen activator
inhibitor-1 improvements observed after 26 weeks of
pioglitazone treatment were not maintained with exenatide
once-weekly treatment.
Safety and tolerability
The most frequent treatment-emergent adverse events in this
assessment period were nausea and diarrhoea (Table 3). Nine
patients experienced 13 treatment-emergent serious adverse
Table 1 Blood pressure and fasting lipids (52-week evaluable population)
Exenatide once-weekly ﬁ
exenatide once-weekly
n = 103
Sitagliptin ﬁ
exenatide once-weekly
n = 116
Pioglitazone ﬁ
exenatide once-weekly
n = 100
Blood pressure (mmHg)
SBP (baseline) 127  1 126  1 126  1
D weeks 26–52 )0.9 ()3.2 to 1.5) )2.7 ()4.9 to )0.5)* )0.6 ()3.0 to 1.7)
D weeks 0–52 )2.9 ()5.4 to )0.4) * )2.9 ()5.3 to )0.6) * )2.2 ()4.7 to 0.3)
DBP (baseline) 80  17 8  17 9  1
D weeks 26–52 )1.2 ()2.7 to 0.3) )0.4 ()1.9 to 1.0) +1.1 ()0.5 to 2.6)
D weeks 0–52 )2.1 ()3.7 to )0.6) * )1.3 ()2.8 to 0.2) )0.4 ()2.0 to 1.1)
Blood lipids (mmol⁄l)
Total cholesterol (baseline) 4.61  0.11 4.59  0.10 4.79  0.11
D weeks 26–52 )0.07 ()0.21 to 0.07) )0.26 ()0.40 to )0.12)* )0.34 ()0.48 to )0.19)*
D weeks 0–52 )0.05 ()0.20 to 0.10) )0.20 ()0.34 to )0.06)* )0.22 ()0.37 to )0.07) *
LDL (baseline) 2.77  0.09 2.74  0.08 2.91  0.10
D weeks 26–52 0.00 ()0.12 to 0.13) )0.09 ()0.20 to 0.03) )0.14 ()0.27 to )0.02)*
D weeks 0–52 )0.03 ()0.17 to 0.10) )0.09 ()0.21 to 0.04) )0.12 ()0.25 to 0.02)
HDL (baseline) 1.06  0.02 1.10  0.02 1.08  0.03
D weeks 26–52 0.00 ()0.03 to 0.03) )0.01 ()0.04 to 0.02) )0.14 ()0.18 to )0.11)*
D weeks 0–52 0.07 (0.04 to 0.11) * 0.06 (0.02 to 0.09) * 0.01 ()0.03 to 0.05)
Triglycerides (baseline) 1.80  0.09 1.63  0.07 1.93  0.09
D weeks 26–52 10% (2 to 19) * 2% ()5 to 9) 11% (3 to 20)*
D weeks 0–52 0% ()7t o8 ) )6% ()12 to 1) )7% ()14 to 1)
Baseline data are mean  se for total cholesterol, LDL and HDL.
Least square mean (95% CI) for change from baseline or week 26 for total cholesterol, LDL and HDL.
Geometric mean  se for triglycerides baseline, and geometric least square mean % change (95% CI) for change from baseline to week 26
for triglycerides.
D Change from previous value
*P < 0.05.
DBP, diastolic blood pressure; SBP, systolic blood pressure.
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one patient was anxiety (n = 2), but did not lead to withdrawal
and was deemed unrelated to study medication. Of the 45
patients who withdrew during this study period, the majority
(64%) withdrew because of withdrawal of consent, investigator
decision, protocol violation, lost to follow-up or for
administrative reasons (Fig. 2). Sixteen patients withdrew
because of either loss of glucose control (n = 4) or an adverse
Table 2 Markers of cardiovascular risk (52-week evaluable population)
Markers of cardiovascular risk
Exenatide once-weekly ﬁ
exenatide once-weekly n = 103
Sitagliptin ﬁ
exenatide once-weekly n = 116
Pioglitazone ﬁ
exenatide once-weekly n = 100
ACR (baseline) 15.31  2.37 11.46  1.27 13.23  1.92
D weeks 26–52 )19% ()31 to )5)* )14% ()26 to 0) )12% ()25 to 4)
D weeks 0–52 )34% ()45 to )20)* )18% ()31 to )3)* )23% ()36 to )7)*
BNP (baseline; pg⁄ml) 9.66  1.00 11.69  1.03 9.60  0.84
D weeks 26–52 )10% ()23 to 6) )16% ()27 to )3)* )26% ()37 to )14)*
D weeks 0–52 )18% ()31 to )3)* )15% ()28 to )1)* )13% ()26 to 3)
hsCRP (baseline; mg⁄l) 2.50  0.24 2.35  0.18 2.33  0.24
D weeks 26–52 )2% ()15 to 12) )8% ()20 to 5) 37% (19 to 58)*
D weeks 0–52 )25% ()35 to )13)* )17% ()27 to )4)* )5% ()18 to 11)
PAI-1 (baseline; ng⁄ml) 39.14  2.29 32.97  1.71 36.18  1.95
D weeks 26–52 16% (4 to 30)* )3% ()12 to 8) 27% (14 to 42)*
D weeks 0–52 4% ()8 to 16) )8% ()18 to 2) 12% (0 to 25)
Baseline data are geometric mean  se. Geometric least square mean % change (95% CI) for change from baseline or week 26.
*P < 0.05.
D Change from previous value
ACR, urinary albumin⁄creatinine ratio; BNP, B-type natriuretic peptide; hsCRP, high-sensitivity C-reactive protein; PAI-1, plasminogen
activator inhibitor 1.
Table 3 Frequent adverse events (‡ 5% in any cohort) and adverse events leading to withdrawal during the open-ended extension period (weeks 26 to 52;
open-label intent-to-treat population)
Exenatide once-weekly ﬁ
exenatide once-weekly n = 119
Sitagliptin ﬁ
exenatide once-weekly n = 130
Pioglitazone ﬁ
exenatide once-weekly n = 115
Frequent adverse events (‡ 5%)
Diarrhoea 10 (8.4) 12 10 (7.7) 13 9 (7.8) 12
Upper respiratory tract infection 7 (5.9) 7 6 (4.6) 7 7 (6.1) 7
Nausea 6 (5.0) 6 14 (10.8) 21 11 (9.6) 13
Vomiting 6 (5.0) 6 5 (3.8) 5 3 (2.6) 4
Nasopharyngitis 6 (5.0) 6 3 (2.3) 3 5 (4.3) 6
Urinary tract infection 4 (3.4) 4 6 (4.6) 10 7 (6.1) 10
Dyspepsia 0 2 (1.5) 2 7 (6.1) 7
Treatment-emergent adverse events leading to withdrawal
Total 2 (1.7) 4 (3.1) 8 (7.0)
Abdominal distension 0 0 1 (0.9)
Abdominal pain 0 0 2 (1.7)
Alanine aminotransferase increased 1 (0.8) 0 0
Blood creatine phosphokinase increased 1 (0.8) 0 0
Cholelithiasis 0 0 1 (0.9)
Decreased appetite 0 1 (0.8) 0
Hepatitus B surface antigen positive 0 0 1 (0.9)
Lipase increased 0 0 1 (0.9)
Nausea 0 2 (1.5) 2 (1.7)
Rash 0 1 (0.8) 0
*Adverse events occurred for the ﬁrst time or worsened after the ﬁrst dose of exenatide once-weekly during the open-label period.
n (%) events for frequent adverse events.
n (%) for individual treatment-emergent adverse events leading to withdrawal (withdrawal may have occurred after week 52).
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emergentadverse eventsleading to withdrawalin more than one
patient were abdominal pain and nausea (Table 3). No cases of
pancreatitis were reported in this 26-week open-label treatment
periodandnocaseswerereportedinpatientsreceivingexenatide
once-weekly during the ﬁrst 26 weeks of the study [3]. No
episodes of major hypoglycaemia occurred; minor
hypoglycaemia incidence was low [n = 5 (1%)] and was
similar among cohorts (exenatide once-weekly-only: 1%;
sitagliptin ﬁ exenatide once-weekly: 2%; pioglitazone ﬁ
exenatide once-weekly: 1%).
Discussion
Glycaemic control and body weight
Exenatide once-weekly elicits continuous exposure to
therapeutic concentrations of the GLP-1 receptor agonist,
exenatide, which acts to increase glucose-dependent insulin
section, decrease inappropriate elevations in postprandial
glucagon, increase satiety and slow gastric emptying [5]. The
continuous exenatide exposure achieved with exenatide once-
weekly has been shown to result in a signiﬁcantly greater fasting
plasma glucose and HbA1c reduction, with similar weight
reduction, compared with the twice daily exenatide
formulation [6]. In the current study, patients who continued
exenatide once-weekly treatment for a total of 52 weeks
maintained the improvements in HbA1c and fasting plasma
glucoseobservedduringtheﬁrst26 weeksoftreatment(52-week
improvements: )1.6% and )1.8 mmol⁄l) and exhibited a
signiﬁcant improvement from original baseline in body weight
()1.8 kg). Similar 52-week improvements in HbA1c, fasting
plasma glucose and weight have previously been demonstrated
[7].
DPP-4inhibitors(e.g.sitagliptin)andGLP-1receptoragonists
(e.g. exenatide) elicit effects through the GLP-1 pathway;
however, distinct differences exist in the mechanism of action
of these compounds. Namely, inhibition of the DPP-4 leads to a
two- to threefold elevation of endogenous GLP-1, while
administration of GLP-1 receptor agonists results in higher
plasma concentrations of agents that bind directly to the GLP-1
receptor. In a short-term trial by DeFronzo et al. comparing
exenatide twice daily with sitagliptin [4], the postprandial
circulating concentration of exenatide, which has similar
potency to GLP-1 [8,9], was approximately fourfold greater
thantheincreaseinpostprandialGLP-1achievedwithsitagliptin
(15 pm; [4]). The greater circulating GLP-1 receptor agonist
concentration observed with exenatide twice daily in the study
by DeFronzo et al. [4] was associated with greater postprandial
glucose control and body weight reduction, and similar fasting
plasma glucose improvement, compared with sitagliptin. The
exenatide molecule in the sustained release (once-weekly)
formulation used in the present study and twice daily
formulation are identical, and the primary mechanism for the
enhanced efﬁcacy of exenatide once-weekly compared with
sitagliptinduringtheﬁrst26weeksofthisstudy[3]waslikelydue
to the continuous exposure to therapeutic concentrations of
exenatide (70 pm; [6]) achieved with once-weekly exenatide.
Thus, the signiﬁcant improvement in HbA1c, fasting plasma
glucose and body weight observed in the present study after
switching from sitagliptin to exenatide once-weekly may be
attributable to the continuous exposure to higher circulating
concentrations of the GLP-1 receptor agonist exenatide.
Pioglitazone, which exerts its anti-hyperglycaemic effects
primarily through decreasing insulin resistance, resulted in a
signiﬁcantly smaller HbA1c improvement and similar fasting
plasma glucose improvement compared with patients treated
with exenatide once-weekly in the ﬁrst phase of this trial [3]. In
the cohort of these patients who completed 52 weeks of
treatment, exenatide once-weekly maintained HbA1c and
fasting plasma glucose improvements; however, weight
signiﬁcantly decreased to a value similar to that observed prior
to pioglitazone treatment.
Markers of cardiovascular risk
Consistent with a previous study of exenatide once-weekly [7],
patients who received exenatide once-weekly for 52 weeks
maintained signiﬁcant systolic blood pressure improvement
(3 mmHg). Systolic blood pressure was not signiﬁcantly
changed in patients originally randomised to sitagliptin during
the initial 26-week period [3]; however, switching to exenatide
once-weekly was associated with signiﬁcantly reduced systolic
blood pressure. Of note, the improvement in systolic blood
pressure was greater in patients with abnormal (‡ 130 mmHg)
systolic blood pressure.
In contrast to a previous assessment of exenatide once-
weekly [7], a signiﬁcant 52-week improvement in HDL
cholesterol, but not total cholesterol and triglycerides, was
observed. The reasons for this discrepancy are unclear, as the
baseline values for these lipid variables were comparable. The
ﬁrst phase of this study [3] conﬁrmed the well-established
effects of pioglitazone [10] to decrease triglycerides and
increase total and HDL cholesterol. Treatment with
exenatide once-weekly in these patients increased triglycerides
and decreased LDL and HDL, such that these lipids were not
signiﬁcantly changed from original baseline. While a signiﬁcant
change in total cholesterol was not observed in patients treated
with exenatide once-weekly for 52 weeks, switching to
exenatide once-weekly from either sitagliptin or pioglitazone
was associated with a signiﬁcant improvement in total
cholesterol.
Overall, treatment with exenatide once-weekly for 52 weeks,
or switching to exenatide once-weekly from sitagliptin, was
associated with favourable 52-week changes in the urinary
albumin⁄creatinine ratio, B-type natriuretic peptide and high-
sensitivity C-reactive protein. Patients who switched from
pioglitazone exhibited a signiﬁcant decrease in B-type
natriuretic peptide, and increases in high-sensitivity C-reactive
protein and plasminogen activator inhibitor-1, such that these
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theurinaryalbumin⁄creatinineratiosigniﬁcantlyimprovedfrom
original baseline. It should be noted that the low mean baseline
values of these markers make clinical interpretations difﬁcult.
Although the mechanism responsible for these improvements
cannot be elucidated from this study, it has been demonstrated
that improvements in microalbuminuria are associated with
improvements in systolic blood pressure and HbA1c [11]; B-type
natriuretic peptide is also interrelated with renal and vascular
function [12]. The differential effects by which exenatide
increased high-sensitivity C-reactive protein to original baseline
values in pioglitazone-treated patients, but was associated with
overall high-sensitivity C-reactive protein improvements in the
other two cohorts are unclear but may be related to the similar
differences in HDL cholesterol change between these treatment
arms(HDLcholesterolhasbeensuggestedtobetheprimarylipid
associatedwithhigh-sensitivityC-reactiveproteinelevation[13];
Table 1).Furtherstudiesarewarrantedtoelucidatetheeffectsof
exenatide once-weekly on these cardiovascular risk markers,
particularly in patients with abnormal values.
Safety and tolerability
As in previous trials with exenatide, mild to moderate
gastrointestinal events were the primary adverse events. Of
note, patients who received exenatide once-weekly during the
initial 26-week treatment period experienced a lower rate of
nausea compared with patients who switched (5 vs. 10–11%),
presumablybecauseofpriorexenatideexposure.Consistentwith
the glucose-dependent nature of enhanced insulin secretion with
exenatide, there were no episodes of major hypoglycaemia
throughoutthestudy.Overall,16patients(4%)withdrewduring
thisperiodasaresultofanadverseeventorlossofglucosecontrol.
Conclusion
Theopen-label,uncontrolled,studydesignlimitstheconclusions
that can be drawn from this study period; however, it should be
noted that, in this phase of the study, neither the patients nor the
investigators were informed of original treatment assignment
(exenatide once-weekly, sitagliptin or pioglitazone) during the
initial 26-week treatment period. The 52-week improvements in
glycaemic control and body weight associated with exenatide
once-weekly-only treatment were similar to those previously
reported [7]. The improvements in glycaemic control, body
weightandsystolicbloodpressureobservedfollowingtheswitch
from sitagliptin to exenatide once-weekly were consistent with
continuous exposure to higher pharmacological concentrations
of a GLP-1 receptor agonist. Furthermore, the maintenance of
glycaemiccontrolandaccompanyingweightreductionobserved
followingtheswitchfrompioglitazonetoexenatideonce-weekly
may be of particular clinical signiﬁcance for some patients. Of
note, exenatide once-weekly has also demonstrated greater
improvement in HbA1c and body weight compared with titrated
insulin glargine, with a lower incidence of hypoglycaemia but
with a greater incidence of gastrointestinal adverse events [14].
Thus, exenatide once-weekly has been demonstrated to elicit
greater HbA1c improvement when directly compared with three
agents that are commonly used after metformin (sitagliptin,
pioglitazone, insulin glargine). The current ﬁndings suggest that
exenatide once-weekly may also be a suitable treatment
alternative in patients with Type 2 diabetes on a background
of metformin who are not currently achieving adequate
glycaemic control with a DPP-4 inhibitor, or in whom
thiazolidinedione-related body weight gain is a concern.
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